Angioimmunoblastic T-cell Lymphoma
Conditions
Brief summary
This study aims to investigate the efficacy and safety of PET regimen combined with Chidamide for angioimmunoblastic T cell lymphoma patients.
Detailed description
Patients enrolled in the trial would be given prednisone, etoposide, thalidomide and Chidamide, and the response and side effects are observed and documented.
Interventions
DRUGChidamide
Chidamide will be given orally 30mg,biw, along with PET regimen (prednisone 100mg,po,qd,d1-5; etoposide 100mg,po,qd,d1-5; thalidomide 100mg,po,qn,d1-14;)
Sponsors
Qingdao University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
single arm trial, patients enrolled would be treated in this arm.
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Pathologically diagnosed as angioimmunoblastic T cell lymphoma (diagnosed by pathologic department in IIIA hospitals or verified by certified institutions), immunohistochemistry should include: CD3, CD4, CD8, CD20, CD10, CD21, CD35, Bcl6, CXCL13, EBER, PD-1, Ki67. 2. At least on measurable focus (≥1.0\*1.0cm by imaging), or at least one evaluable focus; 3. Age 18-75 years, both male and female; 4. ECOG 0-2, KPS≥ 70points; 5. Expected survival ≥3 months; 6. Peripheral blood neutrophil count ≥1.5×10\^9/L, platelet count≥ 75×10\^9/L, Hb≥ 90g/L; 7. Liver function: bilirubin ≤1.5 times of the normal maximum; AST、ALT≤2 times of the normal maximum (for patients with liver infiltration AST、ALT≤3 times of the normal maximum); renal function: blood creatinine ≤2 times the normal maximum; 8. Negative random pregnancy test for fertile women patients within 7 days before enrollment; 9. No radiation therapy, chemotherapy, targeted therapy nor hemopoietic stem cell transplantation within 4 weeks before enrollment; 10. No anti-tumor therapy at enrollment, including herbal therapy, immunotherapy and biologic therapy, symptomatic treatment is not within this range;
Exclusion criteria
1. Women during pregnancy or lactation, and fertile women that are not willing to take contraceptive measurements; 2. Patients with other malignant tumors simultaneously that have not been effectively controlled; 3. Patients with history of using HDAC inhibitors; 4. Patients who are allergic to medicine used in the trial, or have metabolic disorders toward these medicine; 5. Patients with severe active infection; 6. Patients with HIV or syphilis infection; 7. Patients with prolonged QT interval (male \> 450ms，female \> 470ms), or chronic heart failure patients with level III or IV cardiac function; or those have the following heart disease within 6 months before enrollment: acute coronary syndrome, acute heart failure (heart function level III or IV), distinctive ventricular arrhythmias (prolonged ventricular tachycardia, ventricular fibrillation, etc); 8. Patients with history of organ transplantation; 9. Patients with history of thrombosis and embolism; 10. Patients with mental disorders or those who are unable to sign a written consent; 11. Patients with drug abuse or long-time alcoholism that may influence the result of the trial; 12. Patients who do not have capacity of legal transactions; 13. Patients currently in other clinical trials; 14. Those who are recognized as inappropriate for the trial by the investigators;
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Objective remission rate(ORR) | every 3 months until 24 months after the last patient's enrollment | the rate of patients who achieve objective remission after the treatment,including CR (complete remission),CRu (complete remission with unrecovered platelet count) and PR (partial remission). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| duration of remission | from the day of remission to the date of first documented progression，up to 24 months after the last patient's enrollment | from date of complete remission to date of progression, relapse, or death from any cause |
| progression free survival | from the day of treatment to the date of first documented progression，up to 24 months after the last patient's enrollment | from date of inclusion to date of progression, relapse, or death from any cause |
| overall survival | 24 months after the last patient's enrollment | from the date of inclusion to date of death, irrespective of cause |
Countries
China
Contacts
Primary ContactHongwei Xue, MD. PhD
Outcome results
None listed